Zobrazeno 1 - 10
of 557
pro vyhledávání: '"Thomas Filleron"'
Autor:
Quentin Maronnier, Nesrine Robaine, Léonor Chaltiel, Lawrence O. Dierickx, Thibaut Cassou-Mounat, Marie Terroir, Lavinia Vija, Delphine Vallot, Séverine Brillouet, Chloé Lamesa, Thomas Filleron, Olivier Caselles, Frédéric Courbon
Publikováno v:
EJNMMI Physics, Vol 11, Iss 1, Pp 1-14 (2024)
Abstract Background Performance assessment of positron emission tomography (PET) scanners is crucial to guide clinical practice with efficiency. We have already introduced and experimentally evaluated a simulation method allowing the creation of a co
Externí odkaz:
https://doaj.org/article/7196d41f870a4e0a8f7f270bbc38876e
Autor:
Anouchka Modesto, David Tougeron, Pierre Tremolières, Philippe Ronchin, Ariane Darut Jouve, Delphine Argo Leignel, Véronique Vendrely, Olivier Riou, Jérôme Martin-Babau, Samuel Le Sourd, Xavier Mirabel, Thomas Leroy, Florence Huguet, Lucile Montaigne, Isabelle Baumgaertner, Marion Deslandres, Elizabeth Moyal, Catherine Seva, Janick Selves, Philippe Otal, Veronica Pezzella, Rosine Guimbaud, Thomas Filleron, Laurent Quéro
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains the standard of care re
Externí odkaz:
https://doaj.org/article/4418fbc34a394c97ae0e18e1466795e4
Autor:
Yaniss Belaroussi, Fanny Bouteiller, Carine Bellera, David Pasquier, Maurice Perol, Didier Debieuvre, Thomas Filleron, Nicolas Girard, Roland Schott, Simone Mathoulin-Pélissier, Anne-Laure Martin, Sophie Cousin
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCL
Externí odkaz:
https://doaj.org/article/d9b0e457e3b6460188e6d1f1e06df03b
Autor:
Coralie Courtinard, Sophie Gourgou, William Jacot, Matthieu Carton, Olivier Guérin, Laure Vacher, Aurélie Bertaut, Marie-Cécile Le Deley, David Pérol, Patricia Marino, Christelle Levy, Lionel Uwer, Geneviève Perrocheau, Renaud Schiappa, Florence Bachelot, Damien Parent, Mathias Breton, Thierry Petit, Thomas Filleron, Agnès Loeb, Simone Mathoulin Pélissier, Mathieu Robain, Suzette Delaloge, Carine Bellera
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence
Externí odkaz:
https://doaj.org/article/95e587a2739d4813945eb54f7074bcab
Autor:
Antoine Boden, Amélie Lusque, Sabrina Lodin, Marie Bourgouin, Valérie Mauries, Christelle Moreau, Amandine Fabre, Muriel Mounier, Muriel Poublanc, Nathalie Caunes-Hilary, Thomas Filleron
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Neuropathic pain is common in cancer survivorship and is one of the most distressing symptoms for patients previously treated for head and neck cancer. Persistent neuropathic pain, when it is ongoing and uncontrolled, has a detrim
Externí odkaz:
https://doaj.org/article/f97ee87e071049daab092a21ae06f6c7
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Given the inherent challenges of conducting randomized phase III trials in older cancer patients, single-arm phase II trials which assess the feasibility of a treatment that has already been shown to be effective in a younger popu
Externí odkaz:
https://doaj.org/article/5f9863928f2c43abb9f68a4f84c5dad4
Autor:
Ayman Al Saati, Pierre Vande Perre, Julien Plenecassagnes, Julia Gilhodes, Nils Monselet, Bastien Cabarrou, Norbert Lignon, Thomas Filleron, Dominique Telly, Emilie Perello-Lestrade, Viviane Feillel, Anne Staub, Mathilde Martinez, Edith Chipoulet, Gaëlle Collet, Fabienne Thomas, Laurence Gladieff, Christine Toulas
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 14348 (2023)
Even though male breast cancer (MBC) risk encompasses both genetic and environmental aetiologies, the primary risk factor is a germline pathogenic variant (PV) or likely pathogenic variant (LPV) in BRCA2, BRCA1 and/or PALB2 genes. To identify new pot
Externí odkaz:
https://doaj.org/article/87e9553f379a47f987b5d51f4b3062b7
Publikováno v:
The breast journal [Breast J] 2013 Mar-Apr; Vol. 19 (2), pp. 227.
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and as
Externí odkaz:
https://doaj.org/article/1e4648556cd94fd8825881faa3eb2701
Autor:
Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, Jean‐Pierre Lotz, Jacques‐Olivier Bay, Marine Gross‐Goupil, Karim Fizazi, Loïc Mourey, Angelo Paci, Jérôme Guitton, Fabienne Thomas, Bénédicte Lelièvre, Joseph Ciccolini, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Stéphane Culine, Thomas Filleron, Etienne Chatelut
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
ABSTRACT Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area u
Externí odkaz:
https://doaj.org/article/301fe9ecb34d4726a60f64295b13ac50